BRPI0607097A2 - peptìdeos de papiloma vìrus l2 n-terminais para a indução de anticorpos de neutralização amplamente cruzada - Google Patents

peptìdeos de papiloma vìrus l2 n-terminais para a indução de anticorpos de neutralização amplamente cruzada

Info

Publication number
BRPI0607097A2
BRPI0607097A2 BRPI0607097-3A BRPI0607097A BRPI0607097A2 BR PI0607097 A2 BRPI0607097 A2 BR PI0607097A2 BR PI0607097 A BRPI0607097 A BR PI0607097A BR PI0607097 A2 BRPI0607097 A2 BR PI0607097A2
Authority
BR
Brazil
Prior art keywords
protein
peptide
papilloma virus
neutralizing antibodies
cross
Prior art date
Application number
BRPI0607097-3A
Other languages
English (en)
Inventor
John T Schiller
Diana V Pastrana
Ratish Gambhira
Douglas R Lowy
Richard B S Roden
Original Assignee
Us Gov Health & Human Serv
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Univ Johns Hopkins filed Critical Us Gov Health & Human Serv
Publication of BRPI0607097A2 publication Critical patent/BRPI0607097A2/pt
Publication of BRPI0607097B1 publication Critical patent/BRPI0607097B1/pt
Publication of BRPI0607097B8 publication Critical patent/BRPI0607097B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PEPTIDEOS DE PAPILOMA VìRUS L2 N-TERMINAIS PARA A INDUçãO DE ANTICORPOS DE NEUTRALIZAçãO AMPLAMENTE CRUZADA. A invenção compreende um método para induzir anticorpos de neutralização amplamente cruzada contra papíloma vírus tipos mucosa e cutâneo ou contra papiloma vírus tipos heterólogos em humanos, compreendendo administrar a um humano em necessidade do mesmo um peptídeo ou proteína imunogênicos (ou polínucleotídeo de codificação por essa razão), onde o peptideo ou proteína imunogênícos é: (a> um peptídeo ou proteína de pelo menos 10 amínoácidos sobrando em comprimento tendo uma seqUência correspondente a tanto uma seqUência a partir dos aminoácídos N-termínal 1-200 de proteína L2 de papiloma vírus (para anticorpos de neutralização cruzada contra papiloma vírus tipos mucosa e cutâneo) quanto uma seqUência a partir de aminoácídos N-termínal 1-88 de proteína L2 papiloma vírus (para anticorpos de neutralização cruzada contra papíloma vírus tipos heterólogos), (b) um peptideo ou proteína de pelo menos 10 aminoácídos sobrando em comprimento com pelo menos identidade de 55% com a seqUência a apartir de (a), ou (c> um peptideo ou proteína como definido em tanto (a) quanto (b), o qual é conjugado ou fundido a uma proteína ou peptídeo diferente de peptídeo ou proteína L2 de papíloma vírus.
BRPI0607097A 2005-02-01 2006-02-01 uso de um peptídeo imunogênico para a fabricação de um medicamento para o tratamento, prevenção ou redução de infecção por papilomavírus BRPI0607097B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US64924905P 2005-02-01 2005-02-01
US60/649,249 2005-02-01
US69765505P 2005-07-07 2005-07-07
US60/697,655 2005-07-07
US75226805P 2005-12-21 2005-12-21
US60/752,268 2005-12-21
PCT/US2006/003601 WO2006083984A1 (en) 2005-02-01 2006-02-01 Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies

Publications (3)

Publication Number Publication Date
BRPI0607097A2 true BRPI0607097A2 (pt) 2009-08-04
BRPI0607097B1 BRPI0607097B1 (pt) 2020-09-24
BRPI0607097B8 BRPI0607097B8 (pt) 2021-05-25

Family

ID=36590144

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607097A BRPI0607097B8 (pt) 2005-02-01 2006-02-01 uso de um peptídeo imunogênico para a fabricação de um medicamento para o tratamento, prevenção ou redução de infecção por papilomavírus

Country Status (8)

Country Link
US (2) US8404244B2 (pt)
EP (1) EP1853307B1 (pt)
JP (1) JP5224821B2 (pt)
CN (1) CN101193653B (pt)
AU (1) AU2006210792B2 (pt)
BR (1) BRPI0607097B8 (pt)
CA (1) CA2596698C (pt)
WO (1) WO2006083984A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2596698C (en) 2005-02-01 2017-05-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies
AU2007297801A1 (en) 2006-07-14 2008-03-27 Sanofi Pasteur Biologics Co. Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
JP2010504760A (ja) 2006-09-29 2010-02-18 サノフィ パスツール バイオロジクス カンパニー 組換え型ライノウイルスベクター
US20100272753A1 (en) * 2006-10-26 2010-10-28 The Johns Hopkins University Recombinant Adenovirus Vaccines
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8278056B2 (en) 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
WO2010129821A1 (en) 2009-05-07 2010-11-11 Oncohealth Corporation Identification of high grade or ≥cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
US8501907B2 (en) 2007-08-10 2013-08-06 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
WO2009059325A2 (en) * 2007-11-02 2009-05-07 The Johns Hopkins University Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection
CN102458440A (zh) 2009-04-10 2012-05-16 约翰·霍普金斯大学 作为广谱人类乳头状瘤病毒(hpv)疫苗的乳头状瘤病毒样颗粒(vlp)
EA022213B1 (ru) 2009-06-25 2015-11-30 Глаксосмитклайн Байолоджикалс С.А. Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
EP3311833A3 (en) * 2009-08-26 2018-07-25 Selecta Biosciences, Inc. Compositions that induce t cell help
US9128094B2 (en) 2010-01-08 2015-09-08 Oncohealth Corp. High throughput cell-based HPV immunoassays for diagnosis and screening of HPV-associated cancers
WO2011100234A2 (en) * 2010-02-09 2011-08-18 Stc.Unm Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods
US9717783B2 (en) 2010-02-09 2017-08-01 Stc.Unm Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods
NZ610460A (en) * 2010-11-19 2015-01-30 Janssen Biotech Inc Immunoglobulin cleavage fragments vaccine compositions
WO2015068101A1 (en) * 2013-11-06 2015-05-14 Shantha Biotechnics Private Limited Papillomavirus vaccine formulations
CN107188967B (zh) * 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN107188966B (zh) * 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779175D1 (de) * 1986-03-21 1992-06-25 Pasteur Institut Bestimmte, von einem papillomavirus-genom abgeleitete dns-sequenzen, deren anwendungen fuer in vitro-diagnostische zwecke und die herstellung von antigenzusammensetzungen.
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
JP2005533855A (ja) * 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
EP1732615A4 (en) * 2004-03-25 2009-09-16 Kentucky Bioproc Llc PRODUCTION OF PEPTIDES IN PLANTS IN THE FORM OF FUSION OF VIRAL ENVELOPE PROTEINS
CA2596698C (en) 2005-02-01 2017-05-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies

Also Published As

Publication number Publication date
WO2006083984A9 (en) 2006-10-26
CN101193653A (zh) 2008-06-04
CN101193653B (zh) 2013-03-27
US20090047301A1 (en) 2009-02-19
US9388221B2 (en) 2016-07-12
EP1853307B1 (en) 2016-12-14
EP1853307A1 (en) 2007-11-14
AU2006210792A1 (en) 2006-08-10
AU2006210792B2 (en) 2012-07-26
WO2006083984A1 (en) 2006-08-10
JP2008530010A (ja) 2008-08-07
CA2596698A1 (en) 2006-08-10
JP5224821B2 (ja) 2013-07-03
US8404244B2 (en) 2013-03-26
BRPI0607097B8 (pt) 2021-05-25
US20130177585A1 (en) 2013-07-11
BRPI0607097B1 (pt) 2020-09-24
CA2596698C (en) 2017-05-16

Similar Documents

Publication Publication Date Title
BRPI0607097A2 (pt) peptìdeos de papiloma vìrus l2 n-terminais para a indução de anticorpos de neutralização amplamente cruzada
ES2505695T3 (es) Composiciones inmunógenas para Streptococcus pyogenes
RS53988B1 (en) IDENTIFICATION OF TUMOR RELATED ANTIGENS FOR DIAGNOSTICS AND THERAPY
MX2019006349A (es) Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
RU2017101436A (ru) Mic-1 слитные белки и их применение
WO2007084583A3 (en) Soluble fragments of the sars-cov spike glycoprotein
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
NZ570553A (en) Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
BR112014016361A2 (pt) ácido nucleico que compreende ou codifica uma alça peduncular de histona e uma sequência poli(a) ou um sinal de poliadenilação para aumentar a expressão de um antígeno patogênico codificado
WO2006052821A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
NZ595063A (en) Polypeptides from neisseria meningitidis
WO2010074575A3 (en) Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
EA201100072A1 (ru) Новые композиции и способы
WO2007008070A3 (en) ADJUVATION THROUGH CROSS-β STRUCTURE
JP2003500040A5 (pt)
TW200510450A (en) Soluble fragments of the SARS-CoV spike glycoprotein
EA201390820A1 (ru) Слитый белок против рака
BRPI0510016A (pt) vetor lentiviral recombinante para expressão de uma proteìna de flaviviridae e aplicações do mesmo como vacina
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
BR112021023957A2 (pt) Peptídeos
NZ596501A (en) Casb7439 constructs
DE60236579D1 (de) Bakteriophagenvermittelte impfung
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
FR2828405B1 (fr) Vaccin anti-coronavirus

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF